-
Europe's surging inflation spreads gloom in stock markets
-
Demuro hopes to deliver Japan a 'magical' Arc victory
-
Truth commission demands compensation for Sweden's Sami people
-
'Devastated' AI scandal author Orelien returns to Quebec
-
Japan win marathon penalty shootout to set up South Korea gold-medal clash
-
US reports firm Q2 economic growth, inflation steady
-
Djokovic grinds out opening-round win at China Open
-
Energy costs spark inflation surge across Europe
-
Northern Ireland police probe blockade of disputed parade
-
Parma appoint Italy World Cup winner Gilardino
-
UK PM Burnham reopens divisive debate on rejoining EU
-
West Indies pile up record 405-7 in second ODI against India
-
Man City future in doubt after guilty verdict
-
Romanian parliament rejects pro-EU PM candidate amid political deadlock
-
'Do something,' begs Iranian woman after death sentence over protests
-
Passenger on rerouted flydubai flight says pilot tried to crash plane
-
China extends 52-year unbeaten record as Games organisers say sorry
-
Russia targets Kyiv power supply as freezing winter approaches
-
In Manchester, people say City scandal is 'shame for football'
-
Haze pushes Kuala Lumpur, Singapore into world's most polluted cities
-
Stocks lacklustre as inflation data weighs on sentiment
-
Dangote's $16bn Kenya refinery 'new chapter' for Africa
-
Israel-bound plane rerouted, pilots wounded in reported fight
-
Ireland coach Hallgrimsson confirms second Israel game will go ahead
-
Truth commission on Sweden's Sami people seeks redress
-
Swift concert attack plan convict fails to get Disney damages
-
Energy costs spark inflation surges in France, Italy
-
Ocon to leave Haas at end of F1 season
-
South Korea break China hearts to reach Asian Games football final
-
Indonesia razes poolside prison 'villas' where whisky, TVs seized
-
Eala storms into Asian Games semi-finals to thrill adoring fans
-
Japan court rules human voice is protected in TikTok AI case
-
Turkey freezes ex-minister's assets as fund crisis grows
-
French inflation jumps to 3% in September on energy costs
-
What we know about the North Korean POW dispute
-
South Korea score late to reach Asian Games football final
-
Most equities rise after oil price plunge, US data in focus
-
Tom Kim defies jet-lag, Kho cards ace as Asian Games golf begins
-
Polar oceans transformed as warming melts ice habitats: research
-
Thai teen rocker Nene aims to tour, write music... and return to school
-
Lost shark becomes viral star in South Korea
-
Ivory Coast clamps down on harmful illegal gold rush
-
Dangote to launch $16bn refinery in Kenya
-
Nagoya mayor says sorry for Asian Games 'inconveniences'
-
North Korean leader 'extremely obese': Seoul spy agency
-
G20 trade officials meet under shadow of tariffs, overcapacity
-
Yankees and pope-backed White Sox start MLB playoffs with wins
-
India's fat dog vote goes viral
-
Malaysia's ex-PM Mahathir in hospital for observation
-
Asian Games crowds in spotlight as 998 see hosts in 50,000 stadium
Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
B.Torres--AT